Gene therapy shot aims to tame wet AMD

NCT ID NCT05984927

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 15 times

Summary

This early-stage study tests a gene therapy called NG101 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 20 adults aged 50-89 who still need frequent eye injections will receive a one-time shot under the retina. The main goal is to check safety, but researchers will also look for signs that the treatment can reduce the need for repeat injections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cincinnati Eye Institute

    Cincinnati, Ohio, 45242, United States

  • Retina Consultants of Texas

    Bellaire, Texas, 77401, United States

  • Sunnybrook Ophthalmology and Vision Services

    Toronto, Ontario, M4N 3M5, Canada

  • Vancouver Coastal Health Research Institute

    Vancouver, British Columbia, V5Z 3N9, Canada

  • Vitreous Retina Macula Specialists of Toronto

    Toronto, Ontario, M8X 2X3, Canada

Conditions

Explore the condition pages connected to this study.